Abl Cytosolic Substrate
Need Assistance?
  • US & Canada:
    +
  • UK: +

Abl Cytosolic Substrate

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl).

Category
Peptide Inhibitors
Catalog number
BAT-016269
CAS number
168202-46-8
Molecular Formula
C64H101N15O16
Molecular Weight
1336.58
Abl Cytosolic Substrate
IUPAC Name
(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-amino-4-carboxybutanoyl]amino]propanoyl]amino]-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid
Synonyms
L-Lysine, L-α-glutamyl-L-alanyl-L-isoleucyl-L-tyrosyl-L-alanyl-L-alanyl-L-prolyl-L-phenylalanyl-L-alanyl-L-lysyl-L-lysyl-; L-Lysine, N2-[N2-[N2-[N-[N-[1-[N-[N-[N-[N-(N-L-α-glutamyl-L-alanyl)-L-isoleucyl]-L-tyrosyl]-L-alanyl]-L-alanyl]-L-prolyl]-L-phenylalanyl]-L-alanyl]-L-lysyl]-L-lysyl]-; L-α-Glutamyl-L-alanyl-L-isoleucyl-L-tyrosyl-L-alanyl-L-alanyl-L-prolyl-L-phenylalanyl-L-alanyl-L-lysyl-L-lysyl-L-lysine; Glu-Ala-Ile-Tyr-Ala-Ala-Pro-Phe-Ala-Lys-Lys-Lys
Related CAS
2918768-10-0 (acetate salt)
Purity
≥95%
Density
1.261±0.06 g/cm3
Boiling Point
1660.4±65.0°C at 760 mmHg
Sequence
EAIYAAPFAKKK
Storage
Store at -20°C
Solubility
Soluble in Water
InChI
InChI=1S/C64H101N15O16/c1-7-36(2)52(78-55(85)39(5)69-56(86)44(68)28-29-51(81)82)62(92)77-49(35-42-24-26-43(80)27-25-42)60(90)70-37(3)53(83)72-40(6)63(93)79-33-17-23-50(79)61(91)76-48(34-41-18-9-8-10-19-41)59(89)71-38(4)54(84)73-45(20-11-14-30-65)57(87)74-46(21-12-15-31-66)58(88)75-47(64(94)95)22-13-16-32-67/h8-10,18-19,24-27,36-40,44-50,52,80H,7,11-17,20-23,28-35,65-68H2,1-6H3,(H,69,86)(H,70,90)(H,71,89)(H,72,83)(H,73,84)(H,74,87)(H,75,88)(H,76,91)(H,77,92)(H,78,85)(H,81,82)(H,94,95)/t36-,37-,38-,39-,40-,44-,45-,46-,47-,48-,49-,50-,52-/m0/s1
InChI Key
CAYYTKIKSCMCIV-AUMVQHBRSA-N
Canonical SMILES
CCC(C)C(C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C)C(=O)NC(C)C(=O)N2CCCC2C(=O)NC(CC3=CC=CC=C3)C(=O)NC(C)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)O)NC(=O)C(C)NC(=O)C(CCC(=O)O)N
1. Development of a protease-resistant reporter to quantify BCR-ABL activity in intact cells
Angela Proctor, Imola G Zigoneanu, Qunzhao Wang, Christopher E Sims, David S Lawrence, Nancy L Allbritton Analyst. 2016 Oct 17;141(21):6008-6017. doi: 10.1039/c6an01378c.
A peptidase-resistant ABL kinase substrate was developed by identifying protease-susceptible bonds on an ABL substrate peptide and replacing flanking amino acids with non-native amino acids. After an iterative design process, the lead, or designed, peptide X-A possesses a six-fold longer life in a cytosolic lysate than that of the starting peptide. The catalytic efficiency (kcat/KM) of purified ABL kinase for the lead peptide (125 s-1 μM-1) is similar to that of the starting peptide (103 s-1 μM-1) demonstrating preservation of the peptide's ability to serve as a kinase substrate. When incubated in cytosolic lysates, the lead peptide is slowly degraded into 4 fragments over time. In contrast, when loaded into intact cells, the peptide is metabolized into 5 fragments, with only 2 of the fragments corresponding to those in the lysate. Thus the two environments possess differing peptidase activities, which must be accounted for when designing peptidase-resistant peptides. In both settings, the substrate is phosphorylated by BCR-ABL providing a readout of BCR-ABL activity. A small panel of tyrosine kinase inhibitors verified the substrate's specificity for BCR-ABL/ABL kinase activity in both lysates and cells in spite of the multitude of other kinases present. The designed peptide X-A acts as a long-lived BCR-ABL kinase reporter in the leukemic cells possessing the BCR-ABL mutation.
2. Synthetic Reprogramming of Kinases Expands Cellular Activities of Proteins
Veronika M Shoba, Dhanushka N P Munkanatta Godage, Santosh K Chaudhary, Arghya Deb, Sachini U Siriwardena, Amit Choudhary Angew Chem Int Ed Engl. 2022 Jul 18;61(29):e202202770. doi: 10.1002/anie.202202770. Epub 2022 May 31.
Phosphorylation-inducing chimeric small molecules (PHICS) can enable a kinase to act at a new cellular location or phosphorylate non-native substrates (neo-substrates)/ sites (neo-phosphorylations).[1, 2] We report a modular design and high-yielding synthesis of such PHICS that endowed multiple new activities to protein kinase C (PKC). For example, while PKC is unable to downregulate the activity of a gain-of-function variant (S180A) of Bruton's tyrosine kinase that evokes B cell malignancy phenotype, PHICS enabled PKC to induce inhibitory neo-phosphorylations on this variant. Furthermore, while PKC typically phosphorylates its membrane-associated substrates, PKC with PHICS phosphorylated multiple cytosol-based neo-substrates (e.g., BCR-ABL). Finally, a PHICS for BCR-ABL induced death of chronic myeloid leukemia cell lines. These studies show the power of synthetic chemistry to expand the chemical and functional diversity of proteins in cells using bifunctional molecules.
3. Abl tyrosine kinase and its substrate Ena/VASP have functional interactions with kinesin-1
MaryAnn Martin, Shawn M Ahern-Djamali, F Michael Hoffmann, William M Saxton Mol Biol Cell. 2005 Sep;16(9):4225-30. doi: 10.1091/mbc.e05-02-0116. Epub 2005 Jun 22.
Relatively little is known about how microtubule motors are controlled or about how the functions of different cytoskeletal systems are integrated. A yeast two-hybrid screen for proteins that bind to Drosophila Enabled (Ena), an actin polymerization factor that is negatively regulated by Abl tyrosine kinase, identified kinesin heavy chain (Khc), a member of the kinesin-1 subfamily of microtubule motors. Coimmunoprecipitation from Drosophila cytosol confirmed a physical interaction between Khc and Ena. Kinesin-1 motors can carry organelles and other macromolecular cargoes from neuronal cell bodies toward terminals in fast-axonal-transport. Ena distribution in larval axons was not affected by mutations in the Khc gene, suggesting that Ena is not itself a fast transport cargo of Drosophila kinesin-1. Genetic interaction tests showed that in a background sensitized by reduced Khc gene dosage, a reduction in Abl gene dosage caused distal paralysis and axonal swellings. A concomitant reduction in ena dosage rescued those defects. These results suggest that Ena/VASP, when not inhibited by the Abl pathway, can bind Khc and reduce its transport activity in axons.
Online Inquiry
Verification code
Inquiry Basket